Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week.

•A matching-adjusted comparison was conducted.•SC peginterferon beta-1a and SC IFN beta-1a were compared.•Annualized relapse rate was lower for SC peginterferon beta-1a.•24-week CDW was significantly lower for SC peginterferon beta-1a.•Clinical-NEDA was significantly higher for SC peginterferon beta-1a.